Valirx (VAL)

 

VAL Share PerformanceMore

52 week high25.2400 18/12/15
52 week low5.6000 05/12/16
52 week change -9.2500 (-57.81%)
4 week volume10,135,977 14/11/16

Media for (VAL)

Presenter: Suzanne Dilly
30/11/2016
Presenter: Suzanne Dilly
02/11/2016

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ValiRx says European patent granted for VAL201

ValiRx said a patent (Anti-Androgen Peptides and Uses Thereof in Cancer Therapy) covering its lead therapeutic compoun...

European Patent Granted for Lead Compound VAL201

RNS Number: 2297R ValiRx PLC 08 December 2016 Va li R x P lc ("ValiRx" or "the Company") EUROPEAN PATENT GRANTED FOR LEAD THERAPEUTIC COMPOUND VAL201 London, UK ., 08 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel techn...

ValiRx loan draw down

ValiRx has drawn down the second tranche of its convertible loan facility with YA Global Master SPV Ltd for the amoun...

Convertible Loan Facility

RNS Number: 8716Q ValiRx PLC 02 December 2016 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Convertible Loan Facility London, UK ., 02 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commerci...

ValiRx notes ValiSeek clinical development update

ValiRx provides a development update on the clinical development of ValiSeek, the joint venture between ValiRx and Tan...

ValiSeek Clinical Development Update

RNS Number: 6038Q ValiRx PLC 01 December 2016 ValiRx Plc ("ValiRx" or "the Company") ValiSeek Clinical Development Update London, UK., 01 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisatio...

ValiRx Plc - ValiSeek Clinical Development Update

Quarterly Update on Clinical Developments

RNS Number: 3594Q ValiRx PLC 29 November 2016 Va li R x P lc ("ValiRx" or "the Company") QUARTERLY UPDATEON CLINICAL DEVELOPMENTS London, UK ., 29 November 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicin...

Fundamental DataMore

EPS-6.66
Dividend yield0 %

Equity Research (VAL)

edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

  • Positive Interview

    www.proactiveinvestors.co.uk/companies/stocktube/6581/valirx-plc-celebrating-particularly-important-european-patent-6581.html Listen especially to the end bit, discussions ...
    8-Dec-2016
    BarmyOwl
  • RNS

    I think the share price is coiled like a spring. Everyone knows the potential and the transformation effect positive results would have on the share price but as ever with drug ...
    8-Dec-2016
    Tired and Confused
  • Re: Todays RNS

    Agreed encouraging statement & Satu took the opportunity of expanding on just the patent award. But whether it helps our SP recover remains to be seen.
    8-Dec-2016
    dave297

Users' HoldingsMore

Users who hold Valirx also hold..
SOUND ENERGY18%
SAREUM17%
RANGE RES.16%
ROCKHOPPER16%
LLOYDS GRP.16%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL